Mabion SA (DE:272)

FRANKFURT:272

272

Mabion SA

RESEARCH TOOLSreports

Mabion SA (272) Price & Analysis

0 Followers

272 Stock Chart & Stats

€1.85

-€0.07(-2.79%)

At close: Jan 08 4:00 PM EST

€1.85

-€0.07(-2.79%)

Day’s Range― - ―

52-Week Range€1.58 - €2.32

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€27.57M

Enterprise Value€139.27M

Total Cash (Recent Filing)€6.59M

Total Debt (Recent Filing)€25.29M

Price to Earnings (P/E)―

Beta0.27

Next Earnings

Sep 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.53

Shares Outstanding16,162,327

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)2.31

Price to Sales (P/S)7.16

P/FCF Ratio-2.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.08

Revenue Forecast (FY)€14.13M

Bulls Say, Bears Say

Bulls Say

Operational EfficiencyMaintaining a positive EBITDA margin indicates operational efficiency, allowing the company to cover its operating expenses and potentially improve profitability over time.

Strong Balance SheetA strong equity position with low financial leverage suggests financial stability, enabling the company to withstand economic fluctuations and invest in growth opportunities.

Cash Flow ImprovementSignificant improvement in free cash flow indicates enhanced cash generation capabilities, providing more flexibility for future investments and operations.

Bears Say

Declining Gross Profit MarginA declining gross profit margin indicates rising costs or pricing pressures, which could erode profitability and limit resources available for growth initiatives.

Negative ProfitabilityNegative profitability highlights issues in cost management or pricing strategy, posing risks to the company's financial health and ability to reinvest in its business.

Declining RevenueA substantial drop in revenue suggests challenges in market demand or competitive positioning, which could impact the company's ability to sustain growth and profitability.

272 FAQ

What was Mabion SA’s price range in the past 12 months?

Mabion SA lowest stock price was €1.58 and its highest was €2.32 in the past 12 months.

What is Mabion SA’s market cap?

Mabion SA’s market cap is €27.57M.

When is Mabion SA’s upcoming earnings report date?

Mabion SA’s upcoming earnings report date is Sep 15, 2026 which is in 97 days.

How were Mabion SA’s earnings last quarter?

Currently, no data Available

Is Mabion SA overvalued?

According to Wall Street analysts Mabion SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Mabion SA pay dividends?

Mabion SA does not currently pay dividends.

What is Mabion SA’s EPS estimate?

Mabion SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mabion SA have?

Mabion SA has 16,162,327 shares outstanding.

What happened to Mabion SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Mabion SA?

Currently, no hedge funds are holding shares in DE:272

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Mabion SA

Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology. The company oversees the full spectrum from research and development to the manufacturing and commercialization of therapies designed to combat a wide range of diseases, including neoplastic (cancer), autoimmune, metabolic, and neurological disorders. Key products in its portfolio include MabionCD20 and MabionHER2. Established in 2007, Mabion S.A. maintains its headquarters in Konstantynów Lódzki, Poland.